Health Care·Biotechnology·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.29 | N/A | -1.75% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.29 | N/A | -1.75% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current market conditions affecting performance. They did not provide a clear outlook for future quarters.
Management did not provide specific revenue guidance for the upcoming quarters.
The company acknowledged challenges in meeting earnings expectations.
BioCryst Pharmaceuticals reported a loss that was slightly worse than expected, which contributed to a 2.68% drop in stock price. The lack of revenue figures and guidance may raise concerns among investors about the company's future performance. Overall, the market reacted negatively due to uncertainty surrounding upcoming quarters.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CHARLES RIV LABORATO
Feb 13, 2012